F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this ...

DelveInsight's "FILSPARI Market Size, Forecast, and Market Insight Report" highlights the details around FILSPARI, the first and only ...

Zibotentan is a novel once daily tablet and works by blocking the endothelin pathway. As prostate cancer advances, this pathway becomes uncontrolled, which then drives the spread of cancer growth.

Hong: Current therapeutic interventions for PAH primarily target three main pathways: the endothelin pathway, the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway and the prostacyclin ...

Given the significant increase in joint pain and osteoarthritis in patients after COVID infection, this research points to a novel therapeutic pathway, positioning endothelin receptor blockers as a ...

Drugs targeting the three traditional treatment pathways (nitric oxide, endothelin, and prostacyclin) significantly increased 6-minute walk distance (6MWD) and reduced the likelihood of clinical ...

In order to help address this issue, Idorsia developed aprocitentan, an endothelin receptor antagonist suited to the treatment of these patients. Idorsia conducted an ambitious clinical program in ...

“Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition. We were ...

“Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition. We were ...

1 Department of Physiology, School of Medicine, Yanbian University, Yanji, China. 2 Institue of Clinical Medicine, Yanbian University, Yanji, China. 3 Key Laboratory of Organism Functional Factors of ...